Comparing BIOVERATIV INC (BIVV) & vTv Therapeutics (VTVT)
BIOVERATIV INC (NASDAQ: BIVV) and vTv Therapeutics (NASDAQ:VTVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.
Valuation and Earnings
This table compares BIOVERATIV INC and vTv Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|BIOVERATIV INC||$1.03 billion||5.88||$441.10 million||N/A||N/A|
|vTv Therapeutics||$119,000.00||470.80||-$52.99 million||($1.68)||-3.44|
BIOVERATIV INC has higher revenue and earnings than vTv Therapeutics.
This is a breakdown of current recommendations and price targets for BIOVERATIV INC and vTv Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BIOVERATIV INC presently has a consensus target price of $60.36, suggesting a potential upside of 7.76%. vTv Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 185.47%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than BIOVERATIV INC.
This table compares BIOVERATIV INC and vTv Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
91.9% of BIOVERATIV INC shares are held by institutional investors. Comparatively, 11.1% of vTv Therapeutics shares are held by institutional investors. 0.8% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BIOVERATIV INC beats vTv Therapeutics on 7 of the 11 factors compared between the two stocks.
BIOVERATIV INC Company Profile
Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person’s blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
vTv Therapeutics Company Profile
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.